Compartment differences of inflammatory activity in chronic obstructive pulmonary disease

Respiratory Research

Volumn 15, Issue 1, 2014, Pages

  Ji, Jie ^a   Von Schéele, Ida ^a   Bergström, Jan ^a   Billing, Bo ^a   Dahlén, Barbro ^a   Lantz, Ann Sofie ^a   Larsson, Kjell ^a   Palmberg, Lena ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Biomarkers; Chronic obstructive pulmonary disease; Saliva; Tumor necrosis factor

Indexed keywords

GELATINASE B; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; SALBUTAMOL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; AUTACOID; BIOLOGICAL MARKER;

ADULT; AGED; BLOOD CHEMISTRY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DENTAL PROCEDURE; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GINGIVA BLEEDING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INFLAMMATION; LUNG ALVEOLUS MACROPHAGE; LUNG FUNCTION; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; PERIODONTAL DISEASE; PREDICTIVE VALUE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SALIVA; SENSITIVITY AND SPECIFICITY; SERUM; SMOKING; SPIROMETRY; SPUTUM EXAMINATION; METABOLISM; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPUTUM;

ADULT; AGED; BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE FLUID; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SALIVA; SPUTUM;

EID: 84906832416     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-014-0104-3     Document Type: Review

References (33)

1. Agusti A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, Vestbo J, Lomas DA, Calverley PM, Wouters E, Crim C, Yates JC, Silverman EK, Coxson HO, Bakke P, Mayer RJ, Celli B. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012, 7(5):e37483. 10.1371/journal.pone.0037483, 22624038.
2. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, Nordestgaard BG. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA 2013, 309(22):2353-2361. 10.1001/jama.2013.5732, 23757083.
3. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996, 153(2):530-534. 10.1164/ajrccm.153.2.8564092, 8564092.
4. He ZH, Chen Y, Chen P, Wu GB, Cai S. Local inflammation occurs before systemic inflammation in patients with COPD. Respirology 2010, 15(3):478-484. 10.1111/j.1440-1843.2010.01709.x, 20210891.
5. Lim S, Roche N, Oliver BG, Mattos W, Barnes PJ, Chung KF. Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. regulation by interleukin-10. Am J Respir Crit Care Med 2000, 162:1355-1360. 10.1164/ajrccm.162.4.9910097, 11029344.
6. Tartaglia LA, Goeddel DV. Two TNF receptors. Immunol Today 1992, 13(5):151-153. 10.1016/0167-5699(92)90116-O, 1322675.
7. Vernooy JH, Kucukaycan M, Jacobs JA, Chavannes NH, Buurman WA, Dentener MA, Wouters EF. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med 2002, 166(9):1218-1224. 10.1164/rccm.2202023, 12403691.
8. Churg A, Zhou S, Wright JL. Series " matrix metalloproteinases in lung health and disease" : matrix metalloproteinases in COPD. Eur Respir J 2012, 39(1):197-209. 10.1183/09031936.00121611, 21920892.
9. Bergstrom J. Tobacco smoking and chronic destructive periodontal disease. Odontology 2004, 92(1):1-8. 10.1007/s10266-004-0043-4, 15490298.
10. Si Y, Fan H, Song YQ, Zhou X, Zhang J, Wang ZM. Association between periodontitis and chronic obstructive pulmonary disease in a Chinese population. J Periodontol 2012, 83(10):1288-1296. 10.1902/jop.2012.110472, 22248220.
11. Bergstrom J, Cederlund K, Dahlen B, Lantz AS, Skedinger M, Palmberg L, Sundblad BM, Larsson K. Dental health in smokers with and without COPD. Plos One 2013, 8(3):e59492. 10.1371/journal.pone.0059492, 23544074.
12. Strandberg K, Ek A, Palmberg L, Larsson K. Fluticasone and ibuprofen do not add to the effect of salmeterol on organic dust-induced airway inflammation and bronchial hyper-responsiveness. J Intern Med 2008, 264(1):83-94. 10.1111/j.1365-2796.2008.01928.x, 18298484.
13. von Scheele I, Larsson K, Dahlen B, Billing B, Skedinger M, Lantz AS, Palmberg L. Toll-like receptor expression in smokers with and without COPD. Resp Med 2011, 105(8):1222-1230. 10.1016/j.rmed.2011.02.012.
14. Larsson BM, Palmberg L, Malmberg PO, Larsson K. Effect of exposure to swine dust on levels of IL-8 in airway lavage fluid. Thorax 1997, 52(7):638-642. 10.1136/thx.52.7.638, 9246137.
15. Larsson K, Tornling G, Gavhed D, Muller-Suur C, Palmberg L. Inhalation of cold air increases the number of inflammatory cells in the lungs in healthy subjects. Eur Respir J 1998, 12(4):825-830. 10.1183/09031936.98.12040825, 9817153.
16. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Calverley PMA, Celli B, Coxson HO, Crim C, Lomas DA, MacNee W, Miller BE, Silverman EK, Tal-Singer R, Wouters E, Rennard SI. Changes in forced expiratory volume in 1 second overtime in COPD. New Engl J Med 2011, 365(13):1184-1192. 10.1056/NEJMoa1105482, 21991892.
17. Berenson CS, Wrona CT, Grove LJ, Maloney J, Garlipp MA, Wallace PK, Stewart CC, Sethi S. Impaired alveolar macrophage response to Haemophilus antigens in chronic obstructive lung disease. Am J Respir Crit Care Med 2006, 174(1):31-40. 10.1164/rccm.200509-1461OC, 16574934.
18. Chen H, Cowan MJ, Hasday JD, Vogel SN, Medvedev AE. Tobacco smoking inhibits expression of proinflammatory cytokines and activation of IL-1R-associated kinase, p38, and NF-kappaB in alveolar macrophages stimulated with TLR2 and TLR4 agonists. J Immunol 2007, 179(9):6097-6106. 10.4049/jimmunol.179.9.6097, 17947684.
19. Birrell MA, Wong S, Catley MC, Belvisi MG. Impact of tobacco-smoke on key signaling pathways in the innate immune response in lung macrophages. J Cell Physiol 2008, 214(1):27-37. 10.1002/jcp.21158, 17541958.
20. Pinto-Plata V, Casanova C, Mullerova H, de Torres JP, Corado H, Varo N, Cordoba E, Zeineldine S, Paz H, Baz R, Cortopassi F, Celli BR. Inflammatory and repair serum biomarker pattern association to clinical outcomes in COPD. Respir Res 2012, 13:71. 10.1186/1465-9921-13-71, 22906131.
21. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995, 152(3):1107-1136. 10.1164/ajrccm.152.3.7663792.
22. Di Francia M, Barbier D, Mege JL, Orehek J. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994, 150(5 Pt 1):1453-1455. 10.1164/ajrccm.150.5.7952575, 7952575.
23. van der Vaart H, Koeter GH, Postma DS, Kauffman HF, ten Hacken NH. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005, 172(4):465-469. 10.1164/rccm.200501-147OC, 15937294.
24. Dentener MA, Creutzberg EC, Pennings HJ, Rijkers GT, Mercken E, Wouters EF. Effect of infliximab on local and systemic inflammation in chronic obstructive pulmonary disease: a pilot study. Respiration 2008, 76(3):275-282. 10.1159/000117386, 18277064.
25. Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, Mahler D, Saadeh C, Siler T, Snell P, Korenblat P, Smith W, Kaye M, Mandel M, Andrews C, Prabhu R, Donohue JF, Watt R, Lo KH, Schlenker-Herceg R, Barnathan ES, Murray J. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175(9):926-934. 10.1164/rccm.200607-995OC, 17290043.
26. Sapey E, Ahmad A, Bayley D, Newbold P, Snell N, Rugman P, Stockley RA. Imbalances between Interleukin-1 and Tumor Necrosis Factor Agonists and Antagonists in Stable COPD. J Clin Immunol 2009, 29(4):508-516. 10.1007/s10875-009-9286-8, 19291375.
27. Yanbaeva DG, Dentener MA, Creutzberg EC, Wouters EF. Systemic inflammation in COPD: is genetic susceptibility a key factor?. COPD 2006, 3(1):51-61. 10.1080/15412550500493436, 17175665.
28. Mukhopadhyay S, Hoidal JR, Mukherjee TK. Role of TNFalpha in pulmonary pathophysiology. Respir Res 2006, 7:125. 10.1186/1465-9921-7-125, 17034639.
29. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000, 1477(1-2):267-283. 10.1016/S0167-4838(99)00279-4, 10708863.
30. Navratilova Z, Zatloukal J, Kriegova E, Kolek V, Petrek M. Simultaneous up- regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease. Respirology 2012, 17(6):1006-1012. 10.1111/j.1440-1843.2012.02197.x, 22591289.
31. Beeh KM, Beier J, Kornmann O, Buhl R. Sputum matrix metalloproteinase-9, tissue inhibitor of metalloprotinease-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. Respir Med 2003, 97(6):634-639. 10.1053/rmed.2003.1493, 12814147.
32. Sethi S, Maloney J, Grove L, Wrona C, Berenson CS. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 173(9):991-998. 10.1164/rccm.200509-1525OC, 16474030.
33. D'Armiento JM, Goldklang MP, Hardigan AA, Geraghty P, Roth MD, Connett JE, Wise RA, Sciurba FC, Scharf SM, Thankachen J, Islam M, Ghio AJ, Foronjy RF. Increased matrix metalloproteinase (MMPs) levels do not predict disease severity or progression in emphysema. Plos One 2013, 8(2):e56352. 10.1371/journal.pone.0056352, 23441181.